Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma
Cell Reports · 2025
DOI: 10.1016/j.celrep.2025.116359 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2025. Verfasst von Alexander Frey und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Yale School of Medicine, New Haven, CT 06511, USA. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Cancer Vaccines, Interleukin-7, mRNA Vaccines. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Although mRNA technologies have reinvigorated cancer vaccine development, the identification of strong antigens with consistent tumor cell expression and generation of durable antigen-specific CD8+ T cell memory remain key challenges. We identified the Merkel cell carcinoma (MCC) large T antigen (LTA) as an optimal vaccine target, essential for tumor cell survival and immunogenic in a cancer with high unmet clinical need. We developed an mRNA vaccine to MCC-LTA in murine studies and patient samples. We showed that antigen loss develops rapidly and causes resistance in mouse models when immunogenic, but non-essential antigens are targeted. To improve T cell response durability, we co-encoded LTA and IL-7, co-localizing proliferative and memory signals spatially and temporally with antigen exposure. IL-7-containing mRNA vaccines improved antigen-specific T cell expansion, memory differentiation, and tumor control. We propose that the principles of antigen essentiality and memory signal co-encoding may be adapted to improve the efficacy of mRNA therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Yale School of Medicine, New Haven, CT 06511, USA.
- Department of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA.
- Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA.
- Department of Pathology, Yale School of Medicine, New Haven, CT 06511, USA.
- Department of Medicine (Oncology), Yale School of Medicine, New Haven, CT 06511, USA; Department of Pathology, Yale School of Medicine, New Haven, CT 06511, USA.
- Department of Immunobiology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Pathology, Yale School of Medicine, New Haven, CT 06511, USA; Department of Dermatology, Yale School of Medicine, New Haven,…
Förderung
- NCI NIH HHS
- National Institutes of Health National Cancer Institute
- National Institutes of Health
Zitieren
APA
Frey, A., Clulo, K., Fei, Y., Dumit, T. C., Scallo, F., Allen, J. W., Chang, E., Perry, C. J., Wirth, L. V., Jacobs, D., Braun, D. A., Bosenberg, M. W., Tran, T. T., Clune, J., Kluger, H. M., Olino, K., & Ishizuka, J. J. (2025). Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma. Cell Reports. https://doi.org/10.1016/j.celrep.2025.116359
Vancouver
Frey A, Clulo K, Fei Y, Dumit TC, Scallo F, Allen JW, et al. Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma. Cell Reports. 2025. doi:10.1016/j.celrep.2025.116359
BibTeX
@article{Frey2025,
author = {Frey, Alexander and Clulo, Kathryn and Fei, Yuewei and Dumit, Therese Cordero and Scallo, Frankie and Allen, Jerry William and Chang, Emily and Perry, Curtis J and Wirth, Lena V and Jacobs, Daniel and Braun, David A and Bosenberg, Marcus W and Tran, Thuy T and Clune, James and Kluger, Harriet M and Olino, Kelly and Ishizuka, Jeffrey J},
title = {Targeting an essential viral oncoprotein with an IL-7-enhanced mRNA vaccine induces durable immunity to Merkel cell carcinoma},
journal = {Cell Reports},
year = {2025},
doi = {10.1016/j.celrep.2025.116359}
}
EUVIMED